Nanobiotix Announces Resumption of Trading Following Pricing of Global Offering

On May 21, 2026, Nanobiotix S.A. announced the resumption of trading for its ordinary shares on Euronext Paris following a temporary halt requested by the company. The trading halt was implemented to facilitate the pricing and allocation process for a significant Global Offering. This offering consists of a public offering of American Depositary Shares (ADSs) in the United States and a concurrent offering of ordinary shares and pre-funded warrants to qualified investors in Europe and other international jurisdictions. Nanobiotix is a late-clinical stage biotechnology company focused on physics-based therapeutic approaches, specifically leveraging its nanotechnology platforms for oncology and other major diseases. The resumption of trading occurred at 3:30 p.m. Paris time (9:30 a.m. New York time) on the same day. The filing serves to update the market on the status of the company's capital raising efforts and the restoration of liquidity for its shares on the regulated market.